Revenue growth is the metric every other quality signal eventually has to answer to. A business can improve margins, buy back shares, and cut costs for a few years without growing revenue — but none of that is sustainable indefinitely. Revenue growth is the input everything else in the income statement ultimately compounds against. This post treats revenue growth as a standalone screening filter: what counts as "good," how to tell durable growth from a one-off spike, and how to combine it without dragging in an entire growth-investing framework.
If you're looking for a full growth-investing strategy — margins, ROIC, valuation, addressable market — see the growth stock screener guide instead. This post is narrower: it's about the single metric, in isolation, the way gross margin and operating margin are treated elsewhere on this blog.
Last updated: July 2026.
What revenue growth measures
Revenue Growth (YoY) = (Current Period Revenue − Prior Period Revenue) ÷ Prior Period Revenue
Most screeners report this on a trailing twelve-month (TTM) or most-recent-fiscal-year basis. A company with €400M revenue this year versus €360M last year has grown revenue 11.1% year-over-year.
Revenue CAGR (multi-year) annualises growth over a longer window — typically 3 or 5 years — and is a better filter than a single-year figure because it smooths out one-off spikes from acquisitions, currency effects, or a single strong contract.
CAGR = (Ending Revenue ÷ Starting Revenue)^(1/n years) − 1
A company growing from €200M to €350M over 5 years has a 5-year revenue CAGR of about 11.8% — even if any individual year within that period was uneven.
Single-year growth vs. multi-year CAGR: use both
A single year of strong revenue growth tells you very little on its own. It could reflect:
- Genuine acceleration in demand
- A large one-off contract or acquisition rolling into the comparison
- A currency tailwind (a European exporter benefiting from EUR weakness against USD or GBP)
- An easy comparison against a depressed prior-year base (post-recession or post-disruption rebound)
Multi-year CAGR filters out most of this noise. A company with 18% single-year growth but only 4% 3-year CAGR is showing a recent inflection — worth investigating why — rather than sustained compounding. A company with 12% single-year growth and 13% 3-year CAGR is showing consistency, which is generally the more investable pattern.
Practical screening approach:
- Filter for 3-year revenue CAGR above a chosen threshold (removes noise from any single unusual year)
- Check that the most recent year's growth isn't wildly below the CAGR (deceleration risk) or wildly above it (potential one-off inflation)
- Only then evaluate quality of that growth — organic vs. acquired, margin trend, cash conversion
What counts as good revenue growth, by sector
| Sector | "Steady grower" | "Strong growth" | Context |
|---|---|---|---|
| Software / SaaS | 10–20% | > 25% | Recurring revenue models can sustain higher rates for longer |
| Healthcare / medtech | 5–12% | > 15% | Demographic tailwinds support steady mid-single to low-double digits |
| Consumer staples (branded) | 2–5% | > 8% | Mature, low-growth category by nature |
| Industrials | 3–7% | > 12% | Cyclical — compare against the industry cycle, not a single year |
| Luxury goods | 5–10% | > 15% | Can swing sharply with macro and China demand cycles |
| Semiconductors | Highly cyclical | > 20% (upcycle) | Single-year figures are close to meaningless without cycle context |
| Utilities (regulated) | 1–4% | > 6% | Growth is structurally capped by regulation |
| Banks / financials | Loan book growth, not revenue | — | Use net interest income growth and loan book growth instead |
The wide dispersion here is the reason a blanket "revenue growth > 15%" filter is a poor screen on its own — it will admit a semiconductor company mid-upcycle (about to reverse) and exclude a perfectly good healthcare compounder growing a genuinely durable 9% a year.
Organic vs. acquired growth
Revenue growth from organic sources (existing operations selling more) and revenue growth from acquisitions are not equally valuable signals:
Organic growth reflects genuine demand, market share gains, or pricing power in the existing business — the kind of growth that compounds without requiring more capital deployment or integration risk.
Acquired growth shows up identically in the headline revenue growth figure but reflects a management decision to buy revenue rather than build it. It's not inherently bad — disciplined serial acquirers can compound value this way — but it needs to be evaluated on different terms: acquisition price discipline, integration track record, and whether debt taken on to fund the deals is manageable (see Debt-to-EBITDA screening).
A quick sense check: if reported revenue growth is well above what you'd expect from the sector's organic growth range (see table above), check recent M&A activity before assuming the growth is organic and durable.
Revenue growth combined with margins
Growth alone says nothing about whether that growth is profitable or capital-efficient. The most informative combined screens pair revenue growth with margin trend:
Revenue growth accelerating + operating margin expanding = genuine operating leverage. Fixed costs are being spread over a larger base, and the business is becoming structurally more profitable as it scales. This is the pattern institutional growth investors specifically look for.
Revenue growth strong + operating margin flat or declining = growth is being bought with opex (sales, marketing, discounting) rather than earned through demand or pricing power. Sustainable in the short run, worth scrutinising over multiple years.
Revenue growth weak + operating margin expanding = a mature, harvestable business. Reasonable for income-oriented screens, but the growth engine has slowed — check whether this is a temporary cyclical trough or a structural ceiling.
Revenue growth weak + operating margin declining = the combination to screen out. No growth and eroding profitability leaves nothing for a valuation re-rating to work with.
Combined growth-quality screen
| Filter | Value |
|---|---|
| Revenue growth (3yr CAGR) | > 8% |
| Operating margin | > 12%, or expanding YoY |
| Net Debt/EBITDA | < 3.0 |
| Market cap | > €200M |
| Sort by | Revenue growth (3yr CAGR) descending |
Common mistakes when screening by revenue growth
Using a single year in isolation: One strong year proves nothing about durability. Always check 3-year CAGR alongside the most recent year's figure.
Applying one growth threshold across all sectors: 15% revenue growth is unremarkable for a semiconductor company mid-cycle and exceptional for a consumer staples company. Compare against sector norms, not an absolute number.
Ignoring currency effects for exporters: European companies with significant non-EUR revenue can show headline growth that's mostly currency translation rather than underlying demand. Where available, check "organic" or "constant currency" growth figures reported by the company alongside the headline number.
Not checking whether growth is acquired: A revenue growth screen with no M&A filter will surface serial acquirers alongside organic compounders, and treat them identically. They carry different risks.
Chasing growth without a valuation check: A stock growing revenue at 20% a year can still be a poor investment at 60x sales. Revenue growth is an input to a thesis, not the thesis itself — pair it with EV/Sales or another valuation filter before acting on it.
Bottom line
Revenue growth is the metric everything else in a quality or growth screen ultimately has to justify itself against — margins, ROIC, and cash conversion all describe how efficiently a company turns growth into value, but growth is what makes the compounding possible in the first place. Screen using multi-year CAGR rather than a single year, calibrate the threshold to the sector, and always pair it with a margin trend check to separate durable, profitable growth from growth that's being bought at the expense of the bottom line.
Frequently asked questions
What is a good revenue growth rate for European stocks?
It depends heavily on sector. For mature, stable sectors like consumer staples or regulated utilities, 3–6% is solid. For software, healthcare, and other structurally growing sectors, 10–20% is a reasonable "steady grower" range, with above 25% considered strong. Comparing a company's growth rate against sector peers is more informative than any single universal threshold.
Should I use single-year revenue growth or multi-year CAGR when screening?
Multi-year CAGR (typically 3 or 5 years) is generally more reliable because it smooths out one-off effects from acquisitions, currency swings, or unusually easy or hard prior-year comparisons. Use single-year growth as a secondary check — a large gap between the most recent year and the multi-year CAGR is worth investigating either way, whether it signals acceleration or deceleration.
How do I know if revenue growth is organic or from acquisitions?
Compare the headline growth rate against what's typical for the sector and check recent M&A activity — an acquisition-heavy company will show revenue growth well above what organic demand in that sector would explain. Many companies disclose organic growth (excluding M&A and currency effects) separately in their financial reporting; where available, this figure is more useful for assessing underlying demand.
Is revenue growth available in European stock screeners?
Yes — revenue growth (both year-over-year and, on more comprehensive screeners, multi-year CAGR) is a standard field for European-listed companies, including small- and micro-cap names with public financial statements.
Screen European stocks by revenue growth → — free, no account required. Filter by revenue growth, operating margin, and valuation across all European exchanges.